Inflammatory breast cancer (IBC) is a rare, aggressive cancer often excluded from clinical trials. Rachel Layman, M.D., and Bora Lim, M.D., discuss the importance of research in this field and what’s on the horizon for clinical trials at MD Anderson Cancer Center.
Inflammatory Breast Cancer (IBC) Clinical Trials at MD Anderson
Featured Speakers:
Rachel Layman, MD | Bora Lim, MD
Rachel Layman, M.D., is a professor of Breast Medical Oncology at MD Anderson Cancer Center.
Learn more about Rachel Layman, M.D.
Bora Lim, M.D., is an associate professor of Breast Medical Oncology at MD Anderson Cancer Center.